AR104935A1 - Formas cristalinas de un inhibidor de histona deacetilasa - Google Patents

Formas cristalinas de un inhibidor de histona deacetilasa

Info

Publication number
AR104935A1
AR104935A1 ARP160101702A ARP160101702A AR104935A1 AR 104935 A1 AR104935 A1 AR 104935A1 AR P160101702 A ARP160101702 A AR P160101702A AR P160101702 A ARP160101702 A AR P160101702A AR 104935 A1 AR104935 A1 AR 104935A1
Authority
AR
Argentina
Prior art keywords
deacetilasa
histona
inhibitor
crystal forms
crystal
Prior art date
Application number
ARP160101702A
Other languages
English (en)
Spanish (es)
Inventor
Liu Gui
Seyedi Farzaneh
H Van Duzer John
Original Assignee
Acetylon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acetylon Pharmaceuticals Inc filed Critical Acetylon Pharmaceuticals Inc
Publication of AR104935A1 publication Critical patent/AR104935A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP160101702A 2015-06-08 2016-06-08 Formas cristalinas de un inhibidor de histona deacetilasa AR104935A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562172629P 2015-06-08 2015-06-08

Publications (1)

Publication Number Publication Date
AR104935A1 true AR104935A1 (es) 2017-08-23

Family

ID=56178492

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101702A AR104935A1 (es) 2015-06-08 2016-06-08 Formas cristalinas de un inhibidor de histona deacetilasa

Country Status (6)

Country Link
US (1) US10464906B2 (enExample)
EP (1) EP3303306B1 (enExample)
JP (1) JP6816036B2 (enExample)
AR (1) AR104935A1 (enExample)
TW (1) TW201718516A (enExample)
WO (1) WO2016200919A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9663825B2 (en) 2012-04-19 2017-05-30 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
MX369349B (es) 2015-06-08 2019-11-06 Acetylon Pharmaceuticals Inc Metodos para hacer inhibidores de la proteina deacetilasa.
ES2973875T3 (es) * 2016-06-09 2024-06-24 Dana Farber Cancer Inst Inc Métodos de uso y combinaciones farmacéuticas de inhibidores de HDAC con inhibidores de BET
EP3496751B1 (en) 2016-08-08 2022-10-19 Acetylon Pharmaceuticals Inc. Pharmaceutical combinations of histone deacetylase 6 inhibitors and cd20 inhibitory antibodies and uses thereof
JP7090611B2 (ja) 2016-11-23 2022-06-24 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド１（ｐｄ－ｌ１）阻害剤とを含む医薬組み合わせ物及びその使用方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
ATE489360T1 (de) 2000-03-24 2010-12-15 Methylgene Inc Inhibitoren der histon-deacetylase
US20050119305A1 (en) 2001-03-21 2005-06-02 Masao Naka Il-6 production inhibitors
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
MXPA04004177A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Derivados de amida como inhibidores de la glicogeno cintasa cinasa 3-beta.
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2005230682B2 (en) 2004-04-05 2010-10-21 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
EP2491926B1 (en) 2005-03-22 2018-05-09 President and Fellows of Harvard College Treatment of protein degradation disorders
CA2620414A1 (en) 2005-08-26 2007-03-01 Methylgene Inc. Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
AU2007345292B2 (en) 2006-02-14 2013-10-31 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
JP5497431B2 (ja) 2006-05-03 2014-05-21 プレジデント アンド フェローズ オブ ハーバード カレッジ ヒストンデアセチラーゼおよびチューブリンデアセチラーゼ阻害剤
US20100278782A1 (en) 2006-06-12 2010-11-04 Vrije Universiteit Brussel Differentiation of rat liver epithelial cells into hepatocyte-like cells
ES2288802B1 (es) 2006-07-07 2008-12-16 Universidad De Granada Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas.
CN101534831B (zh) 2006-09-11 2013-07-17 柯瑞斯公司 包含锌结合基团的取代的酪氨酸抑制剂
EP2255818B1 (en) 2008-02-19 2018-08-22 Earnest Medicine Co., Ltd. Oral or enteral composition useful for recovery of physical functions
US8440716B2 (en) 2008-07-23 2013-05-14 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
US8716326B2 (en) 2009-05-15 2014-05-06 Korea Research Institute Of Chemical Technology Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
EP2638009A4 (en) 2010-01-08 2014-06-11 Harvard College FLUORINATED HDAC HEMMER AND USES THEREOF
EP2526093B1 (en) 2010-01-22 2016-08-17 Acetylon Pharmaceuticals, Inc. Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
CA2800143A1 (en) 2010-05-21 2011-11-24 The Trustees Of Columbia University In The City Of New York Selective hdac inhibitors
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
PL2640709T3 (pl) 2010-11-16 2016-10-31 Związki pirymidynohydroksyamidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania”
JP6169076B2 (ja) 2011-07-20 2017-07-26 ザ ジェネラル ホスピタル コーポレイション 骨疾患の処置のためのヒストン脱アセチル化酵素６選択的阻害剤
US9663825B2 (en) 2012-04-19 2017-05-30 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
HK1213471A1 (zh) 2012-10-12 2016-07-08 The Trustees Of The University Of Pennsylvania 作為蛋白脫乙酰基酶抑制劑的嘧啶羥基酰胺化合物及其使用方法
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
EP2951153B1 (en) 2013-02-01 2019-04-03 Regenacy Pharmaceuticals, LLC Selective hdac3 inhibitors
EP3004141A4 (en) 2013-06-03 2017-05-31 Acetylon Pharmaceuticals, Inc. Histone deacetylase ( hdac) biomarkers in multiple myeloma
JP2016531163A (ja) 2013-09-20 2016-10-06 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｈｄａｃ６阻害物質を用いた、異常なリンパ球の機能に起因する疾患の治療
EP3054952B1 (en) 2013-10-08 2022-10-26 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer
US20150105383A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma
EP3054954A4 (en) * 2013-10-10 2017-12-13 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
EP3055299B1 (en) 2013-10-10 2021-01-06 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
KR20160060143A (ko) 2013-10-11 2016-05-27 에이스틸론 파마수티컬스 인코포레이티드 히스톤 디아세틸라아제 억제제와 면역조절성 약물의 조합물
JP2016534069A (ja) * 2013-10-24 2016-11-04 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｈｄａｃ６阻害剤での多嚢胞性疾患の治療
ES2806258T3 (es) 2013-12-03 2021-02-17 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores
JP7017309B2 (ja) 2013-12-20 2022-02-08 アセチロン ファーマシューティカルズ インコーポレイテッド 多発性骨髄腫におけるヒストン脱アセチル化酵素６（ｈｄａｃ６）バイオマーカー
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
US20150359794A1 (en) 2014-06-13 2015-12-17 Buck Institute For Research On Aging Impairment of the large ribosomal subunit protein rpl24 by depletion or acetylation
MX2017000307A (es) 2014-07-07 2017-11-23 Acetylon Pharmaceuticals Inc Tratamiento de leucemia con inhibidores de histona deacetilasa.
CA2963681A1 (en) 2014-10-08 2016-04-14 Acetylon Pharmaceuticals, Inc. Induction of gata2 by hdac1 and hdac2 inhibitors
US20160158231A1 (en) 2014-12-05 2016-06-09 Vib Vzw Pyrimidine hydroxy amide compounds for treating peripheral neuropathy
US9937174B2 (en) 2014-12-05 2018-04-10 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
HK1251566A1 (zh) 2014-12-12 2019-02-01 Regenacy Pharmaceuticals, Llc 作为hdac1/2抑制剂的呱啶衍生物
WO2016168647A1 (en) 2015-04-17 2016-10-20 Acetylon Pharmaceuticals Inc. Treatment of neuroblastoma with histone deacetylase inhibotrs
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
MX369349B (es) 2015-06-08 2019-11-06 Acetylon Pharmaceuticals Inc Metodos para hacer inhibidores de la proteina deacetilasa.

Also Published As

Publication number Publication date
EP3303306B1 (en) 2020-02-12
US10464906B2 (en) 2019-11-05
EP3303306A1 (en) 2018-04-11
JP6816036B2 (ja) 2021-01-20
TW201718516A (zh) 2017-06-01
US20170001965A1 (en) 2017-01-05
JP2018516946A (ja) 2018-06-28
WO2016200919A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
IL277778B (en) Bcl6 inhibitors
PL4371987T3 (pl) Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1
IL284508A (en) Irreversible inhibitors of menin-mll interaction
PT3793565T (pt) Inibidores mcl-1
PL3638666T3 (pl) Chwastobójczo skuteczne 3-fenyloizoksazolino-5-karboksyamidy amidów kwasu tetrahydro- i dihydrofuranokarboksylowego
IL269812A (en) Ferroportin-inhibitor salts
DK3529241T3 (da) Pireridinderivater som inhibitorer af ubiquitin-specifik protease 7
SI3713919T1 (sl) Kristalinične oblike n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil) fenil)kinolin-8-sulfonamida
DK3746424T3 (da) Erbb/btk-inhibitorer
MA42606A (fr) Sels d'un inhibiteur de lsd1
HUE064559T2 (hu) MAGL inhibitor kristályos formája
IL286218A (en) Solid state forms of ripretinib
DK3261639T3 (da) Substituerede pyrazolforbindelser som serinproteaseinhibitorer
EP3801500A4 (en) Inhibitors of sarm1
EA201791684A1 (ru) Селективные ингибиторы bace1
DK3833662T3 (da) Inhibitorer af protein-protein-interaktionen mellem KEAP-1-NRF2-
DK3833665T3 (da) Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
AR104935A1 (es) Formas cristalinas de un inhibidor de histona deacetilasa
DK3826982T3 (da) Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer
IL282454A (en) Crystalline salts of a plasma kallikrein inhibitor
IL287736A (en) Diamondoid compounds
PL3552017T3 (pl) Związki użyteczne jako inhibitory RIPK1
EP4003986A4 (en) Inhibitor compounds
DK3826983T3 (da) Anvendelse af substituerede 2-thiazoliner som nitrificeringshæmmere

Legal Events

Date Code Title Description
FB Suspension of granting procedure